Ark Invest Rotates Portfolio: Adds Meta and Gene-Editing Names, Trims Alphabet Stake

Cathie Wood’s Ark Invest continued its active trading cadence last week, with the firm’s flagship funds picking up shares of Meta Platforms and several gene-editing companies while reducing exposure to Alphabet Inc. (GOOGL), according to the firm’s latest weekly trade recap.

Ark’s funds are known for publishing their daily transactions, giving investors a running window into how Wood’s team is repositioning around its thematic research — particularly in artificial intelligence, genomic medicine, and next-generation technology platforms. Last week’s moves suggest a shift of weight away from the mega-cap digital advertising complex and toward positions the firm has long characterized as disruptive growth stories.

The trim of Alphabet comes as the stock trades at $338.46, down about 1.3% from its prior close of $342.93, valuing the internet search and cloud company at roughly $4.14 trillion. Alphabet remains one of the largest companies in the Communication Services sector, operating through its Google Services, Google Cloud, and Other Bets segments across North America, Europe, the Middle East, Africa, the Asia-Pacific region, Canada, and Latin America.

Ark’s purchases of gene-editing names align with the firm’s longstanding thesis that advances in CRISPR-based and related technologies could reshape treatment for genetic diseases, a theme central to its Genomic Revolution strategy. The addition to Meta reflects the firm’s public view that social media and advertising platforms are positioned to benefit from AI-driven engagement and monetization improvements.

Portfolio watchers frequently track Ark’s weekly disclosures, though the firm’s high-turnover style means individual trades can reverse quickly and may not signal a lasting change in strategy. The weekly recap covers transactions across the firm’s suite of actively managed ETFs, including its flagship innovation-focused funds.

What to watch

• Alphabet’s upcoming quarterly earnings report and any commentary on cloud growth and AI spending.
• Further daily trade disclosures from Ark’s ETFs showing whether the Alphabet trim extends or reverses.
• Regulatory and clinical developments affecting Ark’s gene-editing holdings.
• Broad market reaction among large Communication Services names as AI-related capital spending updates roll in.

Source: original release